The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Buprenorphine Treatment of Refractory Depression
Abstract
Opiates were used to treat major depression until the mid-1950s. The advent of opioids with mixed agonist-antagonist or partial agonist activity, with reduced dependence and abuse liabilities, has made possible the reevaluation of opioids for this indication. This is of potential importance for the population of depressed patients who are unresponsive to or intolerant of conventional antidepressant agents. Ten subjects with treatment-refractory, unipolar, nonpsychotic, major depression were treated with the opioid partial agonist buprenorphine in an open-label study. Three subjects were unable to tolerate more than two doses because of side effects including malaise, nausea, and dysphoria. The remaining seven completed 4 to 6 weeks of treatment and as a group showed clinically striking improvement in both subjective and objective measures of depression. Much of this improvement was observed by the end of 1 week of treatment and persisted throughout the trial. Four subjects achieved complete remission of symptoms by the end of the trial (Hamilton Rating Scale for Depression scores < or = 6), two were moderately improved, and one deteriorated. These findings suggest a possible role for buprenorphine in treating refractory depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Buprenorphine has antidepressant effects when used for both opioid use disorder and treatment-resistant depression (279-284)”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [279]
In the citing paper
“Overall, six clinical trials [41,42,43,44,45,46]—of which three were randomized, double-blind and placebo controlled studies [41,44,45]—and one clinical case [47], including a total of 216 subjects with TRD treated with BUP in mono-therapy or together with an opioid antagonist (naloxone or samidorphan) were included.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin [42] treated 10 TRD subjects with BUP, according to tolerance and clinical benefits, with a maximum daily dosage of 1.8 mg. After four to six weeks, seven patients showed clinically striking improvements in both subjective and objective measures of depression.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Taken together, according to the included studies, BUP has a rapid antidepressant and anti-suicidal action: in fact, this psychoactive compound seems to act in about a week after the first administration [41,42,43,44,46,47,48,52].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin and colleagues [42] and Gerra et al. [50] even reported some cases of irritability, anxiety, and dysphoria, which led to drop-out from the study of implicated patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Not all the studies included in this review analyzed the occurrence of side effects related to BUP use but, in those who considered their possible emergence [42,43,44,45,46,50,51], specific side-effects were described in the majority of patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“On the other hand, there are also studies [42,47,48,50,51] suggesting that this action is prolonged in time up to one to three months.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20047-7 · Cited by 226
Regionally selective increases in μ opioid receptor density in the brains of suicide victims
Gross‐Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. R. (1990) · Brain Research · doi:10.1016/0006-8993(90)91301-v · Cited by 221
(1990) · PubMed · Cited by 199
A controlled trial of buprenorphine treatment for opioid dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.267.20.2750 · Cited by 199
Research works printed but not linked: 8
- Carlson, 1963, Am J Psychiatry, 112-, 7
- Lehmann, 1971, Curr Ther Res, 13, 42
- Exstein, 1981, Psychopharmacol Bull, 17, 29
- Resnick, 1992, Psychopharmacol Bull, 28, 109
- Banks, 1979, N Z Med J, 89, 255
- Thase, 1992, J Clin Psychiatry, 53, 5
- Bickel, 1988, J Psychopharmacol Exp Ther, 247, 47
- Harrison, 1988, Psychopharmacol Bull, 24, 9
Cited by
Sorted by citations
Items 101–200 of 352
The Prescription Opioid Addiction Treatment Study: What have we learned
Weiss, R. D., & Rao, V. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.001 · Cited by 68
Latif, Z.-E.-H., Šaltyte Benth, J., Solli, K. K., Opheim, A., Kunoe, N., Krajci, P., Sharma-Haase, K., & Tanum, L. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3537 · Cited by 64
Effects of buprenorphine on responses to social stimuli in healthy adults
Bershad, A. K., Seiden, J. A., & de Wit, H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.09.011 · Cited by 64
NMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 68
Sullivan, M. D., & FERRELL, B. R. (2004) · Journal of Pain · doi:10.1016/j.jpain.2004.10.006 · Cited by 63
Brüning, C. A., Souza, A. C. G., Gai, B. M., Zeni, G. R., & Nogueira, C. W. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.039 · Cited by 63
Opioids:From Physical Pain to the Pain of Social Isolation
Stein, D. J., van Honk, J., Ipser, J., Solms, M., & Panksepp, J. (2007) · CNS Spectrums · doi:10.1017/s1092852900021490 · Cited by 62
Bidlack, J. M., Knapp, B. I., Deaver, D. R., Plotnikava, M., Arnelle, D. R., Wonsey, A. M., Toh, M. F., Pin, S. S., & Namchuk, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249839 · Cited by 62
Liu, X., Xu, Y., Li, S., Wang, Y., Peng, J., Luo, C., Luo, X., Zheng, M., Chen, K., & Jiang, H. (2014) · Journal of Cheminformatics · doi:10.1186/1758-2946-6-33 · Cited by 65
Lovell, K. M., Frankowski, K. J., Stahl, E. L., Slauson, S. R., Yoo, E., Prisinzano, T. E., Aubé, J., & Bohn, L. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00092 · Cited by 61
Marek, G. J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_480 · Cited by 66
Rojas-Corrales, M. O., Berrocoso, E., Gibert‐Rahola, J., & Micó, J. A. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800305 · Cited by 59
Kabli, N., Nguyen, T., Balboni, G., O’Dowd, B. F., & George, S. R. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.115 · Cited by 60
A role for the mu opioid receptor in the antidepressant effects of buprenorphine
Robinson, S. A., Erickson, R. L., Browne, C. A., & Lucki, I. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.050 · Cited by 58
Novel strategies for pharmacotherapy of depression
Maubach, K. A., Rupniak, N. M. J., Kramer, M. S., & Hill, R. G. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80070-2 · Cited by 56
Comorbid Pain, Depression, and Anxiety
Nicolson, S. E., Caplan, J. P., Williams, D. E., & Stern, T. A. (2009) · Harvard Review of Psychiatry · doi:10.3109/10673220903463226 · Cited by 56
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Browne, C. A., Falcón, E., Robinson, S. A., Berton, O., & Lucki, I. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx079 · Cited by 57
Mini-Review: A Brief History of Nitrous Oxide (N2O) Use in Neuropsychiatry
Gillman, M. A. (2018) · Current Drug Research Reviews · doi:10.2174/1874473711666181008163107 · Cited by 55
Benefit-Risk Analysis of Buprenorphine for Pain Management
Hale, M. E., Garofoli, M., & Raffa, R. B. (2021) · Journal of Pain Research · doi:10.2147/jpr.s305146 · Cited by 54
Peckys, D. B., & Hurd, Y. L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00525-1 · Cited by 54
Maremmani, A. G. I., Rovai, L., Pani, P., Pacini, M., Lamanna, F., Rugani, F., Schiavi, E., Dell’Osso, L., & Maremmani, I. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-17 · Cited by 53
Current advances in ligand‐based target prediction
Yang, S., Ye, Q., Ding, J., Yin, M., Lü, A., Chen, X., Hou, T., & Cao, D. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1504 · Cited by 55
Colla, A. R. D. S., Oliveira‐Giacomelli, Á., Pazini, F. L., Rosa, J. M., Manosso, L. M., Cunha, M. P., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.05.015 · Cited by 51
Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain
Pergolizzi, J. V., & Raffa, R. B. (2019) · Journal of Pain Research · doi:10.2147/jpr.s231948 · Cited by 56
Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice
Fichna, J., Janecka, A. E., Piestrzeniewicz, M. K., Costentin, J., & do-Rego, J.-C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301149 · Cited by 51
Kaster, M. P., Budni, J., Santos, A. R. S., & Rodrigues, A. L. S. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.08.026 · Cited by 51
Primary Process Affects and Brain Oxytocin
Panksepp, J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.004 · Cited by 50
Treatment of Refractory Major Depression With Tramadol Monotherapy
Shapira, N. A., Verduin, M. L., & DeGraw, J. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312b · Cited by 50
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice
Almatroudi, A., Husbands, S. M., Bailey, C. P., & Bailey, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115586937 · Cited by 49
Ahmadi, J., Jahromi, M. S., & Ehsaei, Z. (2018) · Trials · doi:10.1186/s13063-018-2843-9 · Cited by 48
Glover, E. M., & Davis, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1112-0 · Cited by 48
New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
Soyka, M. (2015) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s45585 · Cited by 48
The multi-site prescription opioid addiction treatment study: 18-month outcomes
Potter, J. S., Dreifuss, J. A., Marino, E. N., Provost, S. E., Dodd, D. R., Rice, L. S., Fitzmaurice, G. M., Griffin, M. L., & Weiss, R. D. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.009 · Cited by 47
Affective Neuroscience Strategies for Understanding and Treating Depression
Panksepp, J., Wright, J. S., Döbrössy, M. D., Schlaepfer, T. E., & Coenen, V. A. (2014) · Clinical Psychological Science · doi:10.1177/2167702614535913 · Cited by 50
Why does separation distress hurt? Comment on MacDonald and Leary (2005).
Panksepp, J. (2005) · Psychological bulletin · doi:10.1037/0033-2909.131.2.224 · Cited by 40
A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression
Nierenberg, A. A., Katz, J., & D, M. F. M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.001 · Cited by 48
McCann, D. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100503 · Cited by 46
Morgaz, J., Navarrete, R., Muñoz‐Rascón, P., Domínguez, J. M., Fernández-Sarmiento, J. A., Villamandos, R. G., & Granados, M. M. (2013) · Research in Veterinary Science · doi:10.1016/j.rvsc.2013.03.003 · Cited by 46
Berrocoso, E., & Micó, J. A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000236 · Cited by 46
Gerra, G., Zaimovic, A., Raggi, M. A., Moi, G., Branchi, B., Moroni, M., & Brambilla, F. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2006.02.013 · Cited by 46
Ruhm, C. J. (2013) · National Bureau of Economic Research · doi:10.3386/w19287 · Cited by 46
Antidepressant-like effects of buprenorphine in rats are strain dependent
Browne, C. A., Nest, D. S. V., & Lucki, I. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.014 · Cited by 46
Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Saitoh, A., & Yamada, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217314 · Cited by 45
Griffin, M. L., Dodd, D. R., Potter, J. S., Rice, L. S., Dickinson, W., Sparenborg, S., & Weiss, R. D. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.842241 · Cited by 46
Emergence of PTSD in Trauma Survivors With Dementia
van Achterberg, M. E., Rohrbaugh, R. M., & Southwick, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312c · Cited by 45
Depression: A neuropsychoanalytic perspective
Solms, M. (2011) · International Forum of Psychoanalysis · doi:10.1080/0803706x.2011.631582 · Cited by 44
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 45
Effect of Psychiatric Severity on the Outcome of Methadone Maintenance Treatment
Pani, P. P., Maremmani, I., Pacini, M., Lamanna, F., Maremmani, A. G. I., & Dell’Osso, L. (2010) · European Addiction Research · doi:10.1159/000321465 · Cited by 43
Olson, G. A., Olson, R. D., & Kastin, A. J. (1996) · Peptides · doi:10.1016/s0196-9781(96)00225-2 · Cited by 43
Panksepp, J., & Yovell, Y. (2014) · Psychopathology · doi:10.1159/000366208 · Cited by 43
Novel Targets to Treat Depression: Opioid-Based Therapeutics
Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 39
Khushboo, Siddiqi, N. J., Pereira, M. D. L., & Sharma, B. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02780-z · Cited by 40
Behavioral evidence for μ-opioid and 5-HT2A receptor interactions
Marek, G. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01971-x · Cited by 39
Similar Effects of Tramadol and Venlafaxine in Major Depressive Disorder
Reeves, R. R., & Cox, S. K. (2008) · Southern Medical Journal · doi:10.1097/smj.0b013e3181616e66 · Cited by 37
Use of Buprenorphine in treatment of refractory depression—A review of current literature
Stanciu, C. N., Glass, O., & Penders, T. M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.015 · Cited by 37
Effects of opioids on the parental brain in health and disease
Swain, J. E., Ho, S.-H. S., Fox, H. C., Garry, D. J., & Brummelte, S. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100766 · Cited by 38
Brocardo, P. S., Budni, J., Lobato, K. R., Santos, A. R. S., & Rodrigues, A. L. S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.01.004 · Cited by 37
Macroeconomic Conditions and Opioid Abuse
Hollingsworth, A. J., Ruhm, C. J., & Simon, K. I. (2017) · National Bureau of Economic Research · doi:10.3386/w23192 · Cited by 37
Major Depressive Disorder and Kappa Opioid Receptor Antagonists.
Li, W., Sun, H., Chen, H., Yang, X., Li, X., Liu, R., Shao, L., & Qiu, Z. (2016) · PubMed · Cited by 36
Efficacy of tramadol–acetaminophen tablets in low back pain patients with depression
Tetsunaga, T., Tetsunaga, T., Tanaka, M., & Ozaki, T. (2015) · Journal of Orthopaedic Science · doi:10.1007/s00776-014-0674-4 · Cited by 36
AWMF-Leitlinien: Postakutbehandlung bei Störungen durch Opioide
Havemann‐Reinecke, U., Küfner, H., Schneider, U., Günthner, A., Schalast, N., & Vollmer, H. C. (2004) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2004.04.02 · Cited by 34
Mood-Elevating Effects of Opioid Analgesics in Patients With Bipolar Disorder
Schaffer, C. B., NORDAHL, T. E., Schaffer, L. C., & Howe, J. (2007) · Journal of Neuropsychiatry · doi:10.1176/jnp.2007.19.4.449 · Cited by 34
The influence of patient's sex, race and depression on clinician pain treatment decisions
Hirsh, A. T., Hollingshead, N. A., Bair, M. J., Matthias, M. S., Wu, J., & Kroenke, K. (2013) · European Journal of Pain · doi:10.1002/j.1532-2149.2013.00355.x · Cited by 34
Improved memory for reward cues following acute buprenorphine administration in humans
Syal, S., Ipser, J., Terburg, D., Solms, M., Panksepp, J., Malcolm‐Smith, S., Bos, P. A., Montoya, E. R., Stein, D. J., & van Honk, J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.11.009 · Cited by 34
The neuroevolutionary and neuroaffective psychobiology of the prosocial brain
Panksepp, J. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780198568308.013.0012 · Cited by 34
Pharmacological treatment for depression during opioid agonist treatment for opioid dependence
Pani, P. P., Vacca, R., Trogu, E., Amato, L., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008373.pub2 · Cited by 33
The neurobiology of social loss in animals: Some keys to the puzzle of psychic pain in humans.
Panksepp, J. (2010) · American Psychological Association eBooks · doi:10.1037/12351-001 · Cited by 33
Etaee, F., Asadbegi, M., Taslimi, Z., Shahidi, ., Sarihi, A., Asl, S. S., & Komaki, A. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.043 · Cited by 32
Greenwald, M. K. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.08.003 · Cited by 33
Bershad, A. K., Ruiz, N. A., & de Wit, H. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx077 · Cited by 32
The Anti-Suicidal Potential of Buprenorphine: A Case Report
Striebel, J. M., & Kalapatapu, R. K. (2014) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.47.2.g · Cited by 31
Schlauch, R. C., Crane, C. A., Houston, R. J., Molnar, D. S., Schlienz, N. J., & Lang, A. R. (2014) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-014-9462-x · Cited by 32
Zajecka, J., Stanford, A. D., Memisoglu, A., Martin, W. F., & Pathak, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199245 · Cited by 31
Semenkovich, K. A., Chockalingam, R., Scherrer, J. F., Panagopoulos, V. N., Lustman, P. J., Ray, J. M., Freedland, K. E., & Švrakić, D. M. (2014) · Europe PMC (PubMed Central) · Cited by 31
Buprenorphine for depression: The un-adoptable orphan
Callaway, E. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)00158-8 · Cited by 30
Centrally administered apelin-13 induces depression-like behavior in mice
Lv, S., Qin, Y.-J., Wang, H.-T., Xu, N., Yang, Y., & Chen, Q. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.06.003 · Cited by 29
Physical Restraints, Thromboembolism,and Death in 2 Patients
Lazarus, A. L. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312d · Cited by 29
Delta Opioid Receptors and Modulation of Mood and Emotion
Dripps, I. J., & Jutkiewicz, E. M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_42 · Cited by 31
Potentiation strategies for treatment‐resistant depression
Ros, S., Agüera, L., de la Gándara, J., Rojo, E., & de Pedro, J. M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00676.x · Cited by 29
Machado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 29
Management of Addiction Disorders in Pregnancy
Helmbrecht, G. D., & Thiagarajah, S. (2008) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318159d81a · Cited by 28
The effects of buprenorphine on fentanyl withdrawal in rats
Bruijnzeel, A. W., Marcinkiewcz, C. A., Isaac, S. K., Booth, M. M., Dennis, D. M., & Gold, M. S. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0670-2 · Cited by 28
Psychiatric neural networks and neuropharmacology: Selected advances and novel implications
Ghanemi, A. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.01.008 · Cited by 27
Panksepp, J. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.4/jpanksepp · Cited by 27
Long‐Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine
Montalvo, C., Stankiewicz, B., Brochier, A., Henderson, D. C., & Borba, C. P. C. (2019) · American Journal on Addictions · doi:10.1111/ajad.12896 · Cited by 26
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder
Namchuk, A. B., Lucki, I., & Browne, C. A. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10254 · Cited by 29
Poirier, M. F., Laqueille, X., Jalfre, V., Willard, D., Bourdel, M., Fermanian, J., & Olié, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.003 · Cited by 26
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
Peckham, A. M., Cruz, A. D. L., & Dufresne, R. L. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.07.175 · Cited by 26
Maremmani, A. G. I., Rovai, L., Rugani, F., Pacini, M., Lamanna, F., Bacciardi, S., Perugi, G., Deltito, J. A., Dell’Osso, L., & Maremmani, I. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00061 · Cited by 25
COPLAN, P. M., Sessler, N. E., Harikrishnan, V., Singh, R., & Perkel, C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1269596 · Cited by 25
Lithium Intoxication After Administration of AT1 Blockers
Zwanzger, P., Marcuse, A., Boerner, R. J., Walther, A., & Rupprecht, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312e · Cited by 25
Buprenorphine treatment for opioid use disorder: recent progress
Parida, S., Carroll, K. M., Petrakis, I. L., & Sofuoglu, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635454 · Cited by 23
The clinical use of buprenorphine in opiate addiction: evidence and practice
Law, F. D., Myles, J. S., Daglish, M. R. C., & Nutt, D. (2004) · Acta Neuropsychiatrica · doi:10.1111/j.0924-2708.2004.00095.x · Cited by 22
Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 22
Management of Chronic Noncancer Pain in Depressed Patients
Barkin, R. L., Barkin, S. J., Irving, G. A., & GORDON, A. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2470 · Cited by 22
Bailey, S., & Husbands, S. M. (2018) · Neuronal Signaling · doi:10.1042/ns20170145 · Cited by 24
Smith, K. L., Cunningham, J. I., Eyerman, D. J., Dean, R. L., Deaver, D. R., & Sánchez, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.015 · Cited by 21
Addiction Issues in Prescribing Opioids for Chronic Nonmalignant Pain
Weaver, M. F., & Schnoll, S. H. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3180473bec · Cited by 21
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Wang, Q., Long, Y., Hang, A., Zan, G., Shu, X. H., Wang, Y., & Liu, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4292-z · Cited by 19
Metadata
- Authors
- Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O.
- Affiliations
- Harvard University (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1995-02
- Volume
- 15
- Issue
- 1
- Pages
- 49-57
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2063621859
- Cited by
- 346
- References
- 39
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 19 · 2019: 22 · 2018: 25 · 2017: 18 · 2016: 20 · 2015: 20 · 2014: 21 · 2013: 18 · 2012: 13
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-00115)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, treatment-resistant depression, major depressive disorder, antidepressant treatment, opioid side effects
- MeSH terms
- Adult, Aged, Buprenorphine, Depressive Disorder, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
